Bristol-Myers Squibb and Transgene are to test a potential new therapy for advanced non-squamous non-small cell lung cancer (NSCLC) combining a PD-1 immune checkpoint inhibitor, vaccine and chemotherapy.
More than one third (34 percent) of patients with cancer diagnosed as an emergency in England had not visited their GP beforehand, a Cancer Research UK funded study published in the British Journal of General Practice has found.
Eleven new medicines have taken a giant leap towards approval in Europe after winning backing from the European Medicines Agency’s Committee for Medicinal Product for Human Use (CHMP), including two that treat rare neurodegenerative conditions in children.
Bristol-Myers Squibb’s investigational liver disease candidate has hit its targets in a mid-stage trial, supporting further research on the drug as a potential treatment for Nonalcoholic Steatohepatitis (NASH).
AbbVie has released late-stage clinical data showing high cure rates for its experimental ribavirin-free hepatitis C therapy glecaprevir/pibrentasvir (G/P) across the majority of patients infected with the virus.
Novartis has announced the publication of data showing high response rates in patients with the rare blood disorder severe aplastic anaemia (SAA) taking its medicine eltrombopag, supporting its first-line use for the condition.
GW Pharma’s Epidiolex has impressed again in a late-stage trial involving patients with the rare form of epilepsy Lennox-Gastaut Syndrome (LGS), significantly reducing the number of drop seizures experienced.